Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) using a proprietary cell-free platform. The STRO news page on Stock Titan aggregates company announcements, scientific updates, and regulatory disclosures so readers can follow how Sutro’s ADC pipeline and corporate strategy evolve over time.
News about Sutro frequently covers pipeline milestones, such as the initiation of a Phase 1 trial for STRO-004, a tissue factor–targeting exatecan ADC in TF-expressing solid tumors, and preclinical progress for programs like STRO-006 and the dual-payload candidate STRO-227. The company also issues updates on collaborations, including its work with Astellas on dual-payload immunostimulatory ADCs, and presentations at major scientific meetings like the World ADC Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Investors and observers will find corporate and financial communications here as well, including quarterly financial results, details of organizational restructuring aimed at extending the company’s cash runway, and information about actions related to its Nasdaq listing status, such as the 1-for-10 reverse stock split and subsequent confirmation of regained compliance with the minimum bid price requirement.
In addition, Sutro regularly announces participation in healthcare and investor conferences, virtual R&D days, and other events where management discusses the ADC platform, single- and dual-payload programs, and near- and long-term priorities. Bookmark this page to access a consolidated view of Sutro Biopharma’s latest press releases, scientific highlights, and market-facing updates related to its oncology-focused ADC pipeline.
Sutro Biopharma (NASDAQ: STRO) will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 11:30 a.m. EDT. CEO Bill Newell will lead the presentation, which can be accessed via the company’s Investor Relations page. Sutro focuses on oncology therapeutics utilizing advanced protein engineering. Notable candidates include STRO-001 and STRO-002, both in Phase 1 trials for multiple myeloma and ovarian/endometrial cancers, respectively. Sutro's innovative platforms, XpressCF® and XpressCF+™, support its mission to enhance cancer treatment.
Sutro Biopharma (NASDAQ: STRO) reported Q2 2020 financial results, revealing revenue of $9.5 million, down from $10.5 million in Q2 2019. Operating expenses increased to $25.9 million from $24.2 million. Despite challenges, progress continues with clinical trials for STRO-001 and STRO-002, both in Phase 1. Notably, STRO-002 shows promising anti-tumor activity in ovarian cancer patients. The company also recorded a $29.9 million net income, primarily from unrealized gains related to Vaxcyte common stock holdings.
Sutro Biopharma (NASDAQ: STRO) presented new preclinical data for STRO-002, a folate receptor alpha-targeting antibody-drug conjugate, at the 2020 AACR Virtual Annual Meeting II. The data showed STRO-002's potential to induce immunogenic cell death in FolRα positive tumor cells and enhance anti-tumor responses when combined with PD-L1 blockade. Sutro plans to initiate clinical trials for STRO-002 in combination with PD-1/PD-L1 agents in 2021, indicating a promising direction for cancer therapeutics.